Intercept Announces Phase 2 AESOP Trial Evaluating OCA for the Treatment of Patients with PSC
Intercept Pharmaceuticals, Inc. , a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, announced that...
X4 Pharmaceuticals Announces Rare Disease Research Collaboration with Yale University
X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat cancer and rare diseases,...
Teva and Xenon Announce Phase II Study of Topical TV-45070
Teva Pharmaceutical Industries Ltd. and Xenon Pharmaceuticals Inc. announce top-line results in a Phase II study of topical TV-45070 in patients with post-herpetic neuralgia...
DelMar Pharmaceuticals Receives Approval from China’s HGRAC to Initiate Phase 2 Clinical Trial
DelMar Pharmaceuticals , a biopharmaceutical company focused on the development of new cancer therapies announced that the HGRAC, has approved the Company's application to...
Samumed Receives Orphan Drug Designation from FDA for SM04646
Samumed announced that the U.S. FDA has granted SM04646, a novel small molecule Wnt pathway inhibitor, an Orphan Drug Designation (ODD) for IPF: http://bit.ly/2gStpOf...
Is 2017 set to be the year we see a CAR-T therapy approved? Let’s find out from the leaders in the field
Using your body’s own cells, engineering them to target tumors and cure cancer sounds like something from a Sci-Fi movie but it’s not, it’s...
Lilly and Nektar Therapeutics Announce Alliance to Develop and Commercialize NKTR-358
Eli Lilly and Company and Nektar Therapeutics have announced a strategic collaboration to co-develop NKTR-358, a novel immunological therapy discovered by Nektar. NKTR-358, which...
Subscribe Our Newsletter
White Papers
The Future of Digital Health
The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....
Five Best Practices to Deliver Exceptional Multichannel Experiences
A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...
The Impact and Use of Social Media in Pharmacovigilance
Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...